Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Frontotemporal Dementia, Behavioral Variant Clear all
Active, not recruiting Phase 2 Interventional

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

NCT07033481
View directory record Official record
Conditions
Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Interventions
Neflamapimod, Placebo
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Chicago, Illinois • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 3:34 AM EDT
Completed Phase 3 Interventional Results available

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

NCT03325556
View directory record Official record
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Jul 22, 2026, 3:34 AM EDT
Completed No phase listed Observational

Voices Of Individuals: Challenges and Experiences Of bvFTD

NCT04060082
View directory record Official record
Conditions
Frontotemporal Dementia, Frontotemporal Degeneration, Frontotemporal Dementia, Behavioral Variant, FTD
Interventions
Telephone Interview
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 22, 2026, 3:34 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT01626378
View directory record Official record
Conditions
Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions
TRx0237, Placebo
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Up to 79 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
24
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jul 22, 2026, 3:34 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT02245568
View directory record Official record
Conditions
Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia
Interventions
LMTM
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Not listed
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
57
States / cities
Phoenix, Arizona • Fountain Valley, California • Laguna Hills, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Jul 22, 2026, 3:34 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Intranasal Insulin in Frontotemporal Dementia (FTD)

NCT04115384
View directory record Official record
Conditions
Frontotemporal Dementia, Behavioral Variant
Interventions
Novolin-R insulin
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
41 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Jul 22, 2026, 3:34 AM EDT
Enrolling by invitation No phase listed Observational

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

NCT04680130
View directory record Official record
Conditions
PSP, CBD, PCA, LPA, Semantic Dementia, Semantic Aphasia, Behavioral Variant of Frontotemporal Dementia, FTD, PPA, Apraxia of Speech, MSA - Multiple System Atrophy, Parkinson Disease
Interventions
C-11 PiB, AV1451 Tau, C-11 ER176
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 22, 2026, 3:34 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia

NCT06604520
View directory record Official record
Conditions
Fronto-temporal Dementia, Fronto-temporal Lobar Dementia, Frontotemporal Degeneration, Frontotemporal Dementia (FTD), Frontotemporal Dementia, Behavioral Variant, Frontotemporal Dementia
Interventions
Vortioxetine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 22, 2026, 3:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

NCT06064890
View directory record Official record
Conditions
Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal
Interventions
Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101
Procedure · Genetic
Lead sponsor
AviadoBio Ltd
Industry
Eligibility
30 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
3
States / cities
Columbus, Ohio • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 3:34 AM EDT
Completed Not applicable Interventional Results available

Improving Self-Care of Behavioral Variant Frontotemporal Dementia Caregivers

NCT04686266
View directory record Official record
Conditions
Behavioral Variant of Frontotemporal Dementia, Caregiver Stress Syndrome
Interventions
Health Information + Health Coaching
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Jul 22, 2026, 3:34 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT04363684
View directory record Official record
Conditions
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jul 22, 2026, 3:34 AM EDT
Completed Phase 1 Interventional Results available

Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia

NCT02736695
View directory record Official record
Conditions
Primary Progressive Aphasia, Behavioral Variant of Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant
Interventions
F-18 AV 1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 22, 2026, 3:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT03088956
View directory record Official record
Conditions
Frontotemporal Dementia, Behavioral Variant Frontotemporal Dementia
Interventions
Assessments
Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Boca Raton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Jul 22, 2026, 3:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

NCT02365922
View directory record Official record
Conditions
FTLD, Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), Corticobasal Degeneration (CBD), PPA Syndrome, Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis (ALS), Oligosymptomatic PSP (oPSP), Corticobasal Syndrome (CBS)
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
1,489 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Jul 22, 2026, 3:34 AM EDT